R Oskam
Overview
Explore the profile of R Oskam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dorval T, Negrier S, Chevreau C, Avril M, Baume D, Cupissol D, et al.
Cancer
. 1999 Mar;
85(5):1060-6.
PMID: 10091789
Background: The objective of the current study was to evaluate the response rate, survival, and toxicity of treatment with cisplatin and high dose intravenous continuous infusion interleukin-2 (IL-2) with or...
2.
Mainwaring P, Atkinson H, Chang J, Moore J, Hancock B, Guillou P, et al.
Eur J Cancer
. 1997 Aug;
33(9):1388-92.
PMID: 9337679
An open, multicentre non-randomised study was performed to evaluate the activity and toxicity of combination chemoimmunotherapy, consisting of cisplatin, interleukin-2 and interferon-alpha, in metastatic malignant melanoma. Between March 1992 and...
3.
Goey S, Eggermont A, Oskam R, Wiggers T, Bolhuis R, Stoter G
Ann Oncol
. 1996 Mar;
7(3):317-9.
PMID: 8740799
No abstract available.
4.
Houvenaeghel G, Blache J, Arnaud S, Bladou F, Brun J, Chaudet H, et al.
Bull Cancer
. 1995 Dec;
82(12):1052-9.
PMID: 8745672
Preoperative interleukin 2 (IL2) administration has been performed, in order to diminish the post-operative immunodepression in cancer patients. The aim of this study was to compare two different ways of...
5.
Goey S, Eggermont A, Punt C, Slingerland R, Gratama J, Oosterom R, et al.
Br J Cancer
. 1995 Nov;
72(5):1283-8.
PMID: 7577483
Twenty-three patients with pleural mesothelioma stage I-IIA were entered in a study of continuous daily intrapleural infusion of interleukin 2 (IL-2) for 14 days, repeated every 4 weeks. IL-2 was...
6.
Dummer R, Gore M, Hancock B, Guillou P, Grobben H, Becker J, et al.
Cancer
. 1995 Feb;
75(4):1038-44.
PMID: 7842406
Background: Treatment of patients with metastatic melanoma with either dacarbazine or recombinant interleukin-2 (rIL-2) resulted in a response rate of approximately 15%. This study investigates the possible synergism of this...
7.
Heys S, Eremin O, Ruggeri E, Pein F, Rainer H, Oskam R, et al.
Eur J Cancer
. 1995 Jan;
31A(1):19-25.
PMID: 7695972
135 patients with locally advanced or metastatic colorectal cancer were entered into a phase III trial evaluating the efficacy of chemoimmunotherapy [recombinant interleukin 2 (rIL2)/5-fluorouracil (5-FU) and leucovorin (LV)] versus...
8.
Eischen A, Duclos B, Rouyer N, Bergerat J, Hummel M, Oskam R, et al.
Br J Haematol
. 1994 Dec;
88(4):712-22.
PMID: 7819096
Macrophages represent the primary line of host defences in the peritoneal cavity. In order to study the metabolic activity and maturation stage of human resident peritoneal macrophages (PM phi). peritoneal...
9.
Ravaud A, Negrier S, Cany L, Merrouche Y, Le Guillou M, Blay J, et al.
Br J Cancer
. 1994 Jun;
69(6):1111-4.
PMID: 8198979
A double-institution phase II study was performed in patients with metastatic renal cell carcinoma treated subcutaneously (s.c.) with interleukin 2 (IL-2) and alpha-interferon (INF-alpha). Thirty-eight patients were treated over a...
10.
Michon J, Negrier S, Coze C, Mathiot C, Frappaz D, Oskam R, et al.
Prog Clin Biol Res
. 1994 Jan;
385:293-300.
PMID: 7972223
No abstract available.